- $948.24m
- $487.03m
Gossamer Bio gains after rival Aerovate scraps late-stage trial of lead drug
Aerovate at record low after scrapping lung condition drug trial
Aerovate plummets after co scraps late-stage trial of lung condition drug
Aerovate scraps late-stage study of lung disorder drug (updated)
Aerovate scraps late-stage study for hypertension drug after mid-stage trial fails
Brief: Aerovate Therapeutics Announces Results From Phase 2 Trial Evaluating AV-101 For Pulmonary Arterial Hypertension
Brief: Aerovate Therapeutics Inc Files For Mixed Shelf Offering Of Up To $350 Million- SEC Filing
Brief: Aerovate Therapeutics Presents Baseline Data From The Phase 2B Portion Of The Impahct Trial
Aerovate Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Aerovate Therapeutics Inc expected to post a loss of 76 cents a share - Earnings Preview
Aerovate Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Aerovate Therapeutics Inc expected to post a loss of 71 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Aerovate Therapeutics, Kinetik Holdings, Motorola Solutions
Brief: Aerovate Therapeutics Appoints Habib Dable As Board Chair
Brief: Aerovate Therapeutics Announces Simultaneous Completion Of Enrollment In Phase 2B Portion And Enrollment Of First Patient Into Phase 3
U.S. RESEARCH ROUNDUP-Aclaris Therapeutics, Beauty Health Co, Vicarious Surgical
Brief: Aerovate Therapeutics Q3 Basic EPS USD -0.71
U.S. RESEARCH ROUNDUP-Dollar Tree, Hexcel, Humacyte
Aerovate Therapeutics Inc reports results for the quarter ended in June - Earnings Summary